Citations 1
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
Kumar, Shaji , Bensinger, William, Zimmerman, Todd M., Reeder, Craig B. , Berg, Deborah, Hui, Ai-Min, Gupta, Neeraj , Bacco, Alessandra Di , Jiang, Yu , Shou, Yaping, Niesvizky, Rubén, Berenson, James R. , Gupta, Neeraj
Blood | June 6, 2014 | Volume: 124 | Issue: 7 | Pages: 1047-1055
Key Points Weekly oral proteasome inhibitor ixazomib appears generally well tolerated with manageable toxicity, limited grade 1/2 neuropathy. Data show that more than 25% of 30 evaluable relapsed/refractory myeloma patients who received the MTD had clinically meaningful responses.